William Blair analyst Sami Corwin has maintained their bullish stance on RARE stock, giving a Buy rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sami Corwin has given his Buy rating due to a combination of factors that indicate a positive outlook for Ultragenyx Pharmaceutical. The recent $400 million deal with OMERS strengthens the company’s balance sheet, providing financial stability and supporting future product launches, including UX111, DTX401, and UX143. This financial boost reduces the need for additional fundraising, thereby protecting shareholder value from dilution.
Despite a temporary decline in Crysvita revenue due to seasonality, expectations are set for a rebound in the fourth quarter, reflecting the franchise’s underlying strength. Additionally, the focus remains on the upcoming data readout for Setrusumab, with confidence in achieving the primary endpoint. The company’s revenue projections for 2025 and the growth in other products like Dojolvi and Evkeeza further support the positive rating.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $75.00 price target.